NASDAQ:ZVSA ZyVersa Therapeutics (ZVSA) Stock Price, News & Analysis $3.85 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$3.71▼$3.9050-Day Range$3.53▼$6.1852-Week Range$3.41▼$79.80Volume29,323 shsAverage Volume251,653 shsMarket Capitalization$3.20 millionP/E RatioN/ADividend YieldN/APrice Target$120.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get ZyVersa Therapeutics alerts: Email Address ZyVersa Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside3,016.9% Upside$120.00 Price TargetShort InterestHealthy4.04% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.04Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($15.05) to ($25.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.77 out of 5 stars 3.5 Analyst's Opinion Consensus RatingZyVersa Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageZyVersa Therapeutics has received no research coverage in the past 90 days.Read more about ZyVersa Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.04% of the float of ZyVersa Therapeutics has been sold short.Short Interest Ratio / Days to CoverZyVersa Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ZyVersa Therapeutics has recently increased by 76.72%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldZyVersa Therapeutics does not currently pay a dividend.Dividend GrowthZyVersa Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZVSA. Previous Next 2.2 News and Social Media Coverage News SentimentZyVersa Therapeutics has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for ZyVersa Therapeutics this week, compared to 1 article on an average week.MarketBeat Follows3 people have added ZyVersa Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ZyVersa Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.74% of the stock of ZyVersa Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 3.91% of the stock of ZyVersa Therapeutics is held by institutions.Read more about ZyVersa Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ZyVersa Therapeutics are expected to decrease in the coming year, from ($15.05) to ($25.45) per share.Price to Book Value per Share RatioZyVersa Therapeutics has a P/B Ratio of 0.04. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about ZyVersa Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Monument Traders AllianceThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... In fact, it just detected a move happening this MONDAY.See here to see the full details. About ZyVersa Therapeutics Stock (NASDAQ:ZVSA)ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.Read More ZVSA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZVSA Stock News HeadlinesJuly 26 at 3:56 AM | americanbankingnews.comZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest UpdateJuly 25 at 7:57 AM | globenewswire.comZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100July 26, 2024 | Porter & Company (Ad)Obama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.” July 18, 2024 | globenewswire.comZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal ModelJuly 9, 2024 | globenewswire.comZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C.May 17, 2024 | benzinga.comZyVersa Therapeutics Stock (NASDAQ:ZVSA), Earnings Estimates, EPS, and RevenueMay 16, 2024 | investorplace.comZVSA Stock Earnings: ZyVersa Therapeutics Misses EPS for Q1 2024May 15, 2024 | globenewswire.comZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business UpdateJuly 26, 2024 | Porter & Company (Ad)Obama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.” May 14, 2024 | globenewswire.comZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International ConventionApril 29, 2024 | msn.comWhat's Going On With ZyVersa Stock?April 29, 2024 | finance.yahoo.comZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s DiseaseApril 29, 2024 | globenewswire.comZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer's DiseaseApril 4, 2024 | globenewswire.comZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with DiabetesApril 3, 2024 | benzinga.comZyVersa Therapeutics Stock (NASDAQ:ZVSA), Quotes and News SummaryMarch 27, 2024 | markets.businessinsider.comBuy Rating Affirmed: ZyVersa Therapeutics’ Promising Pipeline and Strategic AdvancementsMarch 25, 2024 | globenewswire.comZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateMarch 18, 2024 | globenewswire.comZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney DiseaseSee More Headlines Receive ZVSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ZyVersa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/26/2024Next Earnings (Estimated)8/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ZVSA CUSIPN/A CIK1859007 Webwww.zyversa.com Phone754-231-1688FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Stock Price Target$120.00 High Stock Price Target$120.00 Low Stock Price Target$120.00 Potential Upside/Downside+3,016.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-98,300,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-552.24% Return on Assets-315.58% Debt Debt-to-Equity RatioN/A Current Ratio0.30 Quick Ratio0.30 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$88.98 per share Price / Book0.04Miscellaneous Outstanding Shares830,000Free Float829,000Market Cap$3.20 million OptionableNot Optionable Beta0.66 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Stephen C. Glover (Age 64)Co-Founder, Chairman, CEO & President Comp: $775kMr. Peter Wolfe (Age 56)CFO & Secretary Comp: $477.5kMs. Karen A. Cashmere (Age 72)Chief Commercial Officer Comp: $410kMs. Melda Uzbil O'connellSenior Vice President of Corporate DevelopmentDr. Pablo A. Guzman FACC (Age 74)M.D., Chief Medical Officer, Senior VP of Medical Affairs & Chairman of Renal Scientific Advisory Board Key CompetitorsVaxxinityNASDAQ:VAXXLumos PharmaNASDAQ:LUMOGuardion Health SciencesNASDAQ:GHSIKintara TherapeuticsNASDAQ:KTRAImunonNASDAQ:IMNNView All Competitors ZVSA Stock Analysis - Frequently Asked Questions How have ZVSA shares performed this year? ZyVersa Therapeutics' stock was trading at $9.00 at the beginning of 2024. Since then, ZVSA stock has decreased by 57.2% and is now trading at $3.85. View the best growth stocks for 2024 here. How were ZyVersa Therapeutics' earnings last quarter? ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) issued its quarterly earnings data on Wednesday, May, 15th. The company reported ($4.53) earnings per share for the quarter, missing analysts' consensus estimates of ($3.70) by $0.83. When did ZyVersa Therapeutics' stock split? ZyVersa Therapeutics shares reverse split on Friday, April 26th 2024. The 1-10 reverse split was announced on Friday, April 26th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 26th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of ZyVersa Therapeutics? Shares of ZVSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ZVSA) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZyVersa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ZyVersa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.